The HCT/P Modernization Act of 2025
- Sponsor
- Rep. Crenshaw, Dan [R-TX-2]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jan 13, 2025
Bottom line
The bill aims to enhance transparency, improve regulatory predictability, and gather stakeholder input to modernize the regulation of human cell and tissue products, balancing scientific advancement with public health protection.
What it actually does
This bill directs the Secretary of Health and Human Services, through the FDA, to streamline regulatory oversight of human cell and tissue products (HCT/Ps). It mandates the publication of educational materials and statistics on HCT/P establishments and inspections, amends existing law to broaden the scope of scientific data generation for cellular therapies, establishes a public docket for comments on modernizing HCT/P regulation, and requires a report to Congress with recommendations by September 30, 2026.
Proponents argue
Supporters argue that the current regulatory framework for HCT/Ps can be complex and slow, hindering innovation and timely access to potentially life-saving therapies. They contend that this bill will bring much-needed clarity, efficiency, and scientific rigor to the oversight process, fostering an environment where new treatments can develop safely and reach patients more quickly.
Opponents contend
Critics might express concern that 'streamlining regulatory oversight' could inadvertently lead to a weakening of patient safety standards or a reduction in the FDA's ability to rigorously evaluate the efficacy and safety of these products. They may argue that any modernization must prioritize public health protection above all else, ensuring that regulatory changes do not create loopholes or reduce accountability.
The bill is very short and clearly written, making it highly accessible for a reader to understand its provisions and implications within a short timeframe.
Section 3(a)
Information and Education on Human Cell and Tissue Products
This section requires the FDA to publish educational materials and best practices for interacting with its Tissue Reference Group (TRG) on its public website. It also mandates annual publication of statistics, including the number of registered HCT/P establishments, inspections conducted, and the number and average response times for TRG inquiries. Furthermore, the Secretary must provide information and conduct workshops for stakeholders like industry, academic centers, and patients regarding HCT/P regulation.
Supporters argue
Supporters argue that providing clear information, best practices, and performance metrics for the Tissue Reference Group will reduce regulatory uncertainty for HCT/P developers and manufacturers. This transparency can accelerate the development and availability of innovative therapies by helping establishments navigate the regulatory landscape more efficiently.
Critics contend
No specific opposition is typically raised against provisions that increase transparency and provide educational resources, as these are generally seen as beneficial for all stakeholders. However, some might argue that the administrative burden on the FDA for data collection and publication could divert resources from direct oversight activities.
Tradeoffs
This provision balances the desire for increased transparency and industry guidance with the administrative resources required for data collection, analysis, and dissemination by the FDA.
Section 3(b)
Expansion of Scientific and Regulatory Updates for Cellular Therapies
This section amends Section 3205 of the Food and Drug Omnibus Reform Act of 2022. It expands the scope of 'best practices' that the Secretary is directed to provide. Previously focused on 'best practices for the development of stem cell and other cellular therapies,' the amendment broadens this to include 'best practices on generating scientific data necessary to further facilitate the development of certain human cell-, tissue-, and cellular-based medical products (and the latest scientific information about such products), namely, stem cell and other cellular therapies.'
Section 3(c) and 3(d)
Public Input and Recommendations for HCT/P Regulation Modernization
These sections direct the Secretary to establish a public docket within 60 days to collect written comments on approaches discussed in a public workshop (as per the amended Section 3205) and on modernizing HCT/P regulation, specifically regarding 'minimal manipulation' and 'homologous use' definitions. Following this, by September 30, 2026, the Secretary must summarize these inputs and develop recommendations for Congress concerning HCT/P regulation, considering factors like regulatory burden, scientific developments, access to products, and public health protection.